Stocktoria
NeuroPace Inc NPCE
NeuroPace Inc (NPCE) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $100.0M at a -21.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.99 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.722 |
| Retained earnings / assets | -5.233 |
| EBIT / assets | -0.155 |
| Equity / liabilities | 0.22 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NPCE | NeuroPace Inc | 5/9 | -13.13 | — | +25.1% |
| BBNX | Beta Bionics, Inc. | 4/9 | 6.94 | — | +53.9% |
| KMTS | KESTRA MEDICAL TECHNOLOGIES, LTD. | 5/9 | -0.94 | — | +59% |
| LUNG | Pulmonx Corp | 3/9 | -11.04 | — | +8% |
| ANIK | Anika Therapeutics, Inc. | 5/9 | 6.68 | — | -5.9% |
| DCTH | DELCATH SYSTEMS, INC. | 6/9 | 1.26 | 165.4 | +129.1% |
| OSUR | ORASURE TECHNOLOGIES INC | 2/9 | 6.76 | — | -38.1% |
About NeuroPace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
FAQ
Is NPCE financially healthy?
NeuroPace Inc's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does NPCE pay a dividend?
No, NeuroPace Inc does not currently pay a dividend.
How profitable is NPCE?
In FY2025, NeuroPace Inc had a net margin of -21.5% and a return on equity of -112.8%.
What is the analyst price target for NPCE?
The average Wall-Street price target for NeuroPace Inc is $20.00, about 37.4% above the recent price, from 8 analysts.
Is NPCE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NeuroPace Inc: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.